Cysteines 849 and 942 of human mineralocorticoid receptor are crucial for steroid binding.
To assess the role of each of the four cysteine residues in the hormone binding domain (HBD) of the human mineralocorticoid receptor (hMR), we have separately substituted C808, C849, C910, and C942 into serine. These mutations were created in the G595-K984 hMR receptor fragment which encompasses the DNA binding domain, the hinge region, and the hormone binding domain. Each mutant was further analyzed by steroid binding assays and transactivation assays using wild-type and mutant proteins expressed in vitro in the reticulocyte lysate. While the C910S mutant exhibited similar wild-type G595-K984 receptor binding properties for aldosterone, the C808S mutant affinity was 3.5-fold higher. In contrast, the C849S mutant showed a drastic drop in affinity for aldosterone and the mutant C942S was unable to bind the steroid. Affinities for the antagonist progesterone were also determined. C808S, C849S, and C910S were found to bind progesterone better than aldosterone (about a 2-fold increase in their affinities). Mutant C942S failed to bind any steroid tested (aldosterone, progesterone, cortisol, and the synthetic antagonist RU26752). No change in the specificity toward various agonists and antagonists could be observed with the mutants when compared to the wild-type G595-K984. When transactivation assays were performed, the properties of mutants C808S and C910S were similar to those of the wild-type G595-K984, while mutant C849S showed reduced sensitivity and C942S was devoid of any transcriptional activity. Our data indicate that C849 and C942 are critical for the ligand binding process of hMR. Moreover, C942 might be involved in a direct contact with the 20-keto group of the steroid.
INSERM U300, Faculté de Pharmacie Bat K, Montpellier, France. Brigitte.Lupo@montp.inserm.fr
B
B
Lupo
D
D
Mesnier
G
G
Auzou
D000450:Aldosterone / Q000819:agonists / Q000378:metabolism; D000818:Animals; D001665:Binding Sites / Q000235:genetics; D002460:Cell Line; D003545:Cysteine / Q000235:genetics / Q000378:metabolism*; D005998:Glycine / Q000235:genetics; D000882:Haplorhini; D006801:Humans; D008156:Luciferases / Q000235:genetics; D008239:Lysine / Q000235:genetics; D000451:Mineralocorticoid Receptor Antagonists / Q000378:metabolism; D008901:Mineralocorticoids / Q000037:antagonists & inhibitors / Q000378:metabolism*; D016297:Mutagenesis, Site-Directed; D010446:Peptide Fragments / Q000096:biosynthesis / Q000235:genetics; D011374:Progesterone / Q000378:metabolism; D018161:Receptors, Mineralocorticoid / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D015533:Transcriptional Activation
D000451:Mineralocorticoid Receptor Antagonists; D008901:Mineralocorticoids; D010446:Peptide Fragments; D018161:Receptors, Mineralocorticoid; D000450:Aldosterone; D011374:Progesterone; D008156:Luciferases; D008239:Lysine; D003545:Cysteine; D005998:Glycine